All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are novel strategies to treat low-risk MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What are novel strategies to treat low-risk MDS?

What are novel strategies to treat low-risk MDS?

Platzbecker overviews the current status for luspatercept, used for patients with ring sideroblasts refractory to erythropoiesis-stimulating agents. He then discusses a phase III trial for the telomerase inhibitor imetelstat in transfusion-dependent patients with low-risk MDS that is relapsed/refractory to erythropoiesis-stimulating agents.